The Substantial effects of statins therapy on PCSK9 and adipocytokine in dyslipidemic non-diabetic patients: prevailing motive

Abstract

Background: A large number of cardiovascular disease (CVD) studies infavor use of statins in the management of dyslipidemia owing to their central role in reduction the morbidity and mortality among people suffering from a variety of diseases. Currently the pathophysiological studies on atherosclerosis take a more complex tract than just a lipid buildup problem. Objectives: The purpose of the present study is to evaluate the association between statins therapy and the (adipocytokine and inflammatory) mediators in dyslipidemic non-diabetic patients. Materials and Methods: A total number of 63 dyslipidemic non-diabetic patients were recruited compared with 25 healthy control people. The study were divided into; Group (A): Patients on statins therapy (n=40), Group (B): Patients were not on statins therapy (n=23), and Group(C): Healthy controls (n=25).

Results: There was substantial dyslipidemic status in patients not on statins therapy as matched to patients on statins therapy and healthy controls. TC, TG, VLDL, LDL were greater in patients not on statins therapy. Preprotein convertase subtilisin/kexin type 9 (PCSK9) serum level was higher in statins as compared to non-statins group and controls. Moreover, PCSK9 was greater in rosuvastatin than in atorvastatin treated patients. Retinol bindg protein 4 (RBP4) was lower in statins group compared to non-statins group and controls. While there was no significant difference in the level of RBP4 between atorvastatin and rosuvastatin using patients, although atorvastatin showed a lower value of RBP4. Moreover, the study showed lower level of CRP in statins group (mainly rosuvastatin) than in non-statins group.

Conclusion: Statins enhanced PCSK9 level, with a greater elevation in PCSK9 was observed in rosuvastatin treated patients in comparison to atorvastatin .Statins therapy had a protective effect in lowering RBP4 and CRP in dyslipidemic non diabetic Iraqi patients.